Early Phase Services

More of What You Need for a Stronger Start in Phase I

Your journey from new molecule to new medicine starts with appropriate subjects, world class facilities, and more timely results. PAREXEL provides comprehensive early phase testing services through our own hospital-based clinical units on three continents. This ensures the highest patient safety standards, on-site lab facilities, and quick, in-house access to all of the healthy volunteers and diverse patient populations you need through our global patient database.

We can even perform your Phase I trials across multiple locations at once, thanks to our harmonized Standardized Operating Procedures and integrated, Software-as-a-Service (SaaS)-based technologies that expedite vital decision-making in real time, wherever you need us to be, worldwide. All to get you faster results and more accurate, useful data from First-in-Human through Proof-of-Concept, so your team has the information it needs sooner to continue with the next part of your journey.

Key Offerings 

Phase I, First-in-Human

With participants safety paramount, PAREXEL® Early Phase has developed a superior range of services for the conduct of first-in-man - or First-in-Human (FiH) - and other Phase I safety studies, giving you the assurance that your compound will move into...

read more

Clinical PK/PD and Pharmacometrics Services

The attrition rate in the pharmaceutical industry remains high, with a Phase III failure rate of 40-50%. To address this issue, there is now a larger emphasis on quantitative predictions and translational science from the early exploratory stage...

read more


PAREXEL® Early Phase are world leaders in the performance of ethnobridging clinical trials. As inclusion of Asian countries in global drug development strategies and registration of drugs in the Asia Pacific region has become increasingly important in recent years...

read more

Bioanalytical and Biomarkers

Bioanalysis is the discipline that allows quantitative determination of chemical entities and biomarkers in biological matrices. PAREXEL® Early Phase offers the highest quality bioanalytical services for qualitative and quantitative drug, metabolite, and biomarker analysis in a variety of matrices. 

read more

Key Materials


Starting Stronger in Phase I Through IIA

Adding value from first-in-human through proof-of-concept.Achieve success through early testing of compounds in patients and healthy volunteers. Read more.


The Changing Face of the Early Phase Volunteer

Download a copy of the March 17th Executive Insight article, "The Changing Face of the Early Phase Volunteer," written by Thomas Senderovitz, M.D., Senior Vice President, Clinical Research Services, PAREXEL and Sy Pretorius, M.D., Corporate Vice President & Worldwide Head Early Phase, PAREXEL.